Baxdrostat Shows Significant Blood Pressure Reduction in Resistant Hypertension in Phase III trial Dr. Kamal Kant Kohli16 Oct 2025 7:45 AM ISTBaxdrostat, a novel aldosterone synthase inhibitor, demonstrated a highly clinically meaningful reduction in 24-hour ambulatory systolic blood...
AstraZeneca Gets SEC Nod for New Trastuzumab Deruxtecan Indication in HER2-Positive Solid Tumors Parthika Patel10 Oct 2025 8:09 PM ISTNew Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has recommended approval for an additional...
AstraZeneca to harmonise its listing structure across LSE, STO and NYSE Ruchika Sharma30 Sept 2025 12:00 PM ISTCambridge: AstraZeneca plans to harmonise its share listing structure to deliver a global listing for global investors in a global company. The...
AstraZeneca Koselugo recommended for approval in EU for plexiform neurofibromas in adults with neurofibromatosis type 1 Ruchika Sharma28 Sept 2025 4:45 PM ISTAstraZeneca has announced that Koselugo (selumetinib), an oral, selective MEK inhibitor, has been recommended for approval in the European...
Patent infringement: Factor Bioscience sues AstraZeneca, Cellectis over gene-editing technology Ruchika Sharma27 Sept 2025 5:30 PM ISTBiotech firm Factor Bioscience has filed a lawsuit against Cellectis and AstraZeneca, accusing the companies of allegedly infringing three patents...
AstraZeneca-Daiichi Sankyo get USFDA grants priority review for Enhertu combo for 1st line HER2+ Breast cancer treatment Ruchika Sharma24 Sept 2025 12:46 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's supplemental Biologics License Application (sBLA) for Enhertu (trastuzumab deruxtecan) in combination...
AstraZeneca-Amgen Tezspire recommended for approval in EU for chronic rhinosinusitis with nasal polyps Ruchika Sharma22 Sept 2025 2:00 PM ISTCambridge: AstraZeneca and Amgen's Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult...
AstraZeneca Faces NPPA Heat Over Symbicort Pricing, Slapped Rs 60 Crore Showcause Notice Parthika Patel13 Sept 2025 8:24 PM ISTNew Delhi: AstraZeneca Pharma India Limited has received a show cause notice from the National Pharmaceutical Pricing Authority (NPPA), which has...
AstraZeneca Gets SEC Approval to Conduct Phase IV Trial of Hyperkalemia Drug Sodium Zirconium Cyclosilicate Susmita Roy11 Sept 2025 1:58 PM ISTNew Delhi: The Subject Expert Committee (SEC) functioning under the Central Drug Standard Control Organisation (CDSCO), has granted approval to the...
AstraZeneca announces Rs 176 crore investments in India to expand Chennai GITC Ruchika Sharma8 Sept 2025 11:36 AM ISTChennai: Global biopharmaceutical giant AstraZeneca has announced fresh investments of Rs 176 crore in India, reinforcing its commitment to...
AstraZeneca eyes year-end filing for BP drug Baxdrostat Ruchika Sharma1 Sept 2025 12:26 PM ISTBengaluru: AstraZeneca plans to seek regulatory approval for its experimental blood pressure drug, baxdrostat, by the end of the year, a senior...
AstraZeneca Faces Setback as CDSCO Panel Rejects Seloken XL Prescribing Update Susmita Roy31 Aug 2025 1:00 PM ISTNew Delhi: Rejecting the proposal of AstraZeneca Pharma for the update of prescribing information (PI) of Metoprolol Succinate Prolonged Release...
